Compare EPAC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | ADMA |
|---|---|---|
| Founded | 1910 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1994 | 2012 |
| Metric | EPAC | ADMA |
|---|---|---|
| Price | $35.14 | $11.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $48.00 | $25.67 |
| AVG Volume (30 Days) | 398.3K | ★ 8.6M |
| Earning Date | 03-25-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ 8.97 | N/A |
| EPS | ★ 0.67 | 0.60 |
| Revenue | ★ $616,899,000.00 | $42,219,783.00 |
| Revenue This Year | $5.60 | $27.46 |
| Revenue Next Year | $5.56 | $22.11 |
| P/E Ratio | $52.51 | ★ $18.16 |
| Revenue Growth | 4.65 | ★ 43.85 |
| 52 Week Low | $33.66 | $7.21 |
| 52 Week High | $45.42 | $25.67 |
| Indicator | EPAC | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 46.12 |
| Support Level | $34.89 | $7.21 |
| Resistance Level | $37.46 | $16.61 |
| Average True Range (ATR) | 0.86 | 0.48 |
| MACD | 0.06 | 0.35 |
| Stochastic Oscillator | 19.65 | 85.27 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.